PIRS - Pieris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue29,10125,2755,8312,931.931
Cost of Revenue----
Gross Profit29,10125,2755,8312,931.931
Operating Expenses
Research Development40,99021,78519,1997,826.352
Selling General and Administrative18,94218,0849,3918,786.614
Non Recurring----
Others----
Total Operating Expenses59,93239,86928,59016,612.966
Operating Income or Loss-30,831-14,594-22,759-13,681.035
Income from Continuing Operations
Total Other Income/Expenses Net3,765-1,950122-173.74
Earnings Before Interest and Taxes-30,831-14,594-22,759-13,681.035
Interest Expense----
Income Before Tax-27,066-16,544-22,637-13,854.775
Income Tax Expense-3121,103162203.866
Minority Interest----
Net Income From Continuing Ops-26,754-17,647-22,799-14,058.641
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-26,754-17,647-22,799-14,058.641
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-26,754-17,647-22,799-14,058.641